AlphaQuest LLC Buys 7,818 Shares of Twist Bioscience Co. (NASDAQ:TWST)

AlphaQuest LLC raised its stake in Twist Bioscience Co. (NASDAQ:TWST) by 216.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,422 shares of the company’s stock after acquiring an additional 7,818 shares during the period. AlphaQuest LLC’s holdings in Twist Bioscience were worth $531,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of TWST. Wilmington Savings Fund Society FSB bought a new stake in Twist Bioscience in the 3rd quarter valued at $34,000. Van ECK Associates Corp increased its holdings in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after acquiring an additional 267 shares during the last quarter. US Bancorp DE increased its holdings in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after acquiring an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC bought a new stake in Twist Bioscience in the 3rd quarter valued at $95,000. Finally, KBC Group NV increased its holdings in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after acquiring an additional 1,226 shares during the last quarter.

Twist Bioscience Price Performance

TWST stock opened at $39.32 on Thursday. The stock has a market cap of $2.35 billion, a PE ratio of -11.63 and a beta of 2.15. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a 50-day moving average price of $46.18 and a 200 day moving average price of $45.39.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.75) EPS. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TWST. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. Robert W. Baird boosted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Finally, Wolfe Research assumed coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $54.40.

Insider Buying and Selling at Twist Bioscience

In other news, CFO Adam Laponis sold 5,886 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now owns 110,096 shares in the company, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,654 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $74,264.60. Following the completion of the sale, the chief executive officer now owns 673,064 shares of the company’s stock, valued at approximately $30,220,573.60. This represents a 0.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,845 shares of company stock valued at $1,603,945 in the last three months. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.